Cytosorbents (NASDAQ:CTSO) CEO Buys $100,454.40 in Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan acquired 251,136 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were bought at an average cost of $0.40 per share, with a total value of $100,454.40. Following the transaction, the chief executive officer directly owned 1,734,099 shares in the company, valued at $693,639.60. This trade represents a 16.93% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $0.48 on Thursday. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $29.95 million, a P/E ratio of -2.51 and a beta of 1.35. The company has a 50 day moving average price of $0.54 and a 200 day moving average price of $0.63. Cytosorbents Corporation has a fifty-two week low of $0.37 and a fifty-two week high of $1.39.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Cytosorbents had a negative return on equity of 235.57% and a negative net margin of 31.85%.The company had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $9.40 million. Equities research analysts forecast that Cytosorbents Corporation will post -0.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CTSO shares. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.38.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Avenir Corp increased its stake in Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after purchasing an additional 147,261 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares in the last quarter. CM Management LLC boosted its holdings in shares of Cytosorbents by 14.6% in the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock valued at $944,000 after acquiring an additional 188,372 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Cytosorbents in the third quarter valued at about $161,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Cytosorbents in the third quarter valued at about $105,000. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.